A recent clinical trial
has investigated the effect of a drug called tranexamic acid in reducing blood loss during cesarean section.
A C-section (or cesarean birth) is a surgical procedure used to deliver a baby when a vaginal delivery can't be done safely. Cesarean section is the surgical delivery of a baby through a cut (incision) made in the mother's abdomen and uterus. It is performed when doctors believe that it is safer for the mother, the baby, or both. Increasingly women are making an informed choice of getting a C-section instead of a normal vaginal delivery due to the fear of pain encountered during normal delivery.
Postpartum hemorrhage, or excessive bleeding after childbirth, is a serious complication that can lead to maternal death. It is more common in women who have had multiple cesarean sections.
Tranexamic Acid (TXA) is a medication used to prevent excessive bleeding during surgical procedures. However, its use during C-sections is controversial as the data available is insufficient to justify its use.
A clinical trial was conducted recently aimed at investigating the effect of using tranexamic acid to reduce blood loss during cesarean section.
The clinical study published in the American Journal of Obstetrics and Gynecology involved 110 women undergoing their 2nd or 3rd C sections divided into two groups. 55 women received 1g of tranexamic acid just before and after surgery while the remaining 55 women did not receive this drug. The women were followed for 24h at the end of which blood loss was calculated by laboratory testing.
The results of the clinical trial showed that the average blood loss in the tranexamic group was 2272 ml compared to the other group in which the average blood loss was 2407 ml.
These results demonstrated that tranexamic acid did not significantly reduce blood loss during the C-section as the percentage of blood loss in both groups was similar.
However, the results of this clinical study did show that the risk of blood clots in the blood vessels of the patients receiving tranexamic acid was lower than in the other group.
The findings of this study have important implications for clinical practice, particularly for women who have had multiple cesarean deliveries as it shows that the use of tranexamic acid in these patients is not justified and other treatments for reducing blood loss should be sought out.
In conclusion, this clinical study
has highlighted that tranexamic acid should not be used to reduce blood loss during cesarean section as the results do not show any benefit to justify its use. Furthermore, it emphasizes that new drugs should be sought for the reduction of blood loss.